News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,733 Results
Type
Article (19974)
Company Profile (128)
Press Release (312631)
Section
Business (105378)
Career Advice (879)
Deals (18534)
Drug Delivery (97)
Drug Development (50772)
Employer Resources (79)
FDA (7684)
Job Trends (7742)
News (185865)
Policy (17330)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (733)
Accelerated approval (1)
Adcomms (17)
Allergies (40)
Alliances (27827)
ALS (52)
Alzheimer's disease (623)
Antibody-drug conjugate (ADC) (86)
Approvals (7697)
Artificial intelligence (131)
Autoimmune disease (11)
Automation (4)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (93)
Biotechnology (57)
Bladder cancer (29)
Brain cancer (18)
Breast cancer (102)
Cancer (990)
Cardiovascular disease (99)
Career advice (711)
Career pathing (20)
CAR-T (53)
Cell therapy (145)
Cervical cancer (5)
Clinical research (42567)
Collaboration (439)
Compensation (146)
Complete response letters (22)
COVID-19 (1097)
CRISPR (21)
C-suite (135)
Cystic fibrosis (56)
Data (1026)
Decentralized trials (2)
Denatured (18)
Depression (23)
Diabetes (133)
Diagnostics (1806)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (72)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (56)
Earnings (38932)
Editorial (29)
Employer branding (10)
Employer resources (73)
Events (48448)
Executive appointments (406)
FDA (8224)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (298)
Gene editing (45)
Generative AI (17)
Gene therapy (139)
GLP-1 (571)
Government (1831)
Grass and pollen (2)
Guidances (18)
Healthcare (5903)
Huntington's disease (13)
IgA nephropathy (18)
Immunology and inflammation (76)
Indications (17)
Infectious disease (1173)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (22)
Intellectual property (51)
Interviews (116)
IPO (7366)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (21)
Layoffs (272)
Leadership (13)
Legal (4113)
Liver cancer (31)
Lung cancer (149)
Lymphoma (81)
Machine learning (2)
Management (30)
Manufacturing (187)
MASH (45)
Medical device (1960)
Medtech (1963)
Mergers & acquisitions (11400)
Metabolic disorders (466)
Multiple sclerosis (44)
NASH (20)
Neurodegenerative disease (43)
Neuropsychiatric disorders (20)
Neuroscience (904)
NextGen: Class of 2025 (2357)
Non-profit (906)
Northern California (1010)
Now hiring (20)
Obesity (293)
Opinion (189)
Ovarian cancer (33)
Pain (63)
Pancreatic cancer (35)
Parkinson's disease (77)
Partnered (9)
Patents (128)
Patient recruitment (45)
Peanut (16)
People (33369)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13325)
Phase II (18009)
Phase III (14467)
Pipeline (618)
Podcasts (68)
Policy (101)
Postmarket research (1618)
Preclinical (4643)
Press Release (29)
Prostate cancer (57)
Psychedelics (16)
Radiopharmaceuticals (160)
Rare diseases (228)
Real estate (3170)
Recruiting (29)
Regulatory (12476)
Reports (22)
Research institute (817)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (1)
RSV (23)
Schizophrenia (55)
Series A (55)
Series B (31)
Service/supplier (6)
Sickle cell disease (34)
Southern California (972)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2008)
State (2)
Stomach cancer (9)
Supply chain (49)
The Weekly (47)
United States (9526)
Vaccines (263)
Venture capitalists (27)
Webinars (11)
Weight loss (233)
Women's health (14)
Worklife (7)
Date
Today (15)
Last 7 days (302)
Last 30 days (1346)
Last 365 days (17021)
2025 (3990)
2024 (17670)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24870)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (408)
Alabama (22)
Alaska (1)
Arizona (63)
Arkansas (8)
Asia (24840)
Australia (3208)
California (2373)
Canada (1057)
China (307)
Colorado (94)
Connecticut (96)
Delaware (66)
Europe (51255)
Florida (408)
Georgia (51)
Idaho (16)
Illinois (232)
India (18)
Indiana (167)
Iowa (3)
Japan (108)
Kansas (60)
Kentucky (17)
Louisiana (1)
Maine (4)
Maryland (353)
Massachusetts (1993)
Michigan (45)
Minnesota (130)
Mississippi (1)
Missouri (26)
Montana (10)
Nebraska (11)
Nevada (15)
New Hampshire (8)
New Jersey (959)
New Mexico (21)
New York (690)
North Carolina (479)
North Dakota (2)
Northern California (1010)
Ohio (80)
Oklahoma (5)
Oregon (21)
Pennsylvania (557)
Puerto Rico (10)
Rhode Island (13)
South America (606)
South Carolina (3)
Southern California (972)
Tennessee (38)
Texas (317)
Utah (53)
Virginia (78)
Washington D.C. (41)
Washington State (203)
Wisconsin (19)
332,733 Results for "athira pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
February 28, 2025
·
9 min read
BioForest
Athira Pharma to Participate in Upcoming May 2024 Conferences
Athira Pharma, Inc. announced that Company management will participate in the following upcoming investor conferences in May.
May 2, 2024
·
1 min read
Business
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.
May 15, 2024
·
13 min read
Press Releases
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
November 8, 2024
·
8 min read
Business
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced the appointment of Javier San Martin, M.D., as Chief Medical Officer.
April 15, 2024
·
8 min read
Drug Development
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease.
April 11, 2024
·
6 min read
Drug Development
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma, Inc. announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, an oral, small molecule positive modulator of the neurotrophic hepatocyte growth factor system in development for the treatment of amyotrophic lateral sclerosis.
June 11, 2024
·
5 min read
Press Releases
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
September 17, 2024
·
7 min read
Drug Development
Athira Pharma to Participate in Upcoming June ConferencesManagement to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that Company management will participate in the following upcoming investor conferences in June.
May 29, 2024
·
4 min read
1 of 33,274
Next